ADJUNCTIVE, LOW-DOSE INTRACORONARY RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) VERSUS PLACEBO FOR PRIMARY PCI IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

Registry ID

STRIVE.2018

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

HAMILTON HEALTH SCIENCES CORPORATION

Start date

2018-11-09

Last update

2018-09-12

Conditions

• MYOCARDIAL INFARCTION

Related clinical trials

• Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome
• EVALUATION OF AN ASPIRIN-FREE STRATEGY WITH TICAGRELOR IN PATIENTS WITH A MYOCARDIAL INFARCTION TREATED MEDICALLY ALONE (PANTHEON)
• ARTEMIS - EFFECTS OF ZILTIVEKIMAB VERSUS PLACEBO ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION.
• A PHASE IIB, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEDI6570 IN PARTICIPANTS WITH A PRIOR MYOCARDIAL INFARCTION, PERSISTENT INFLAMMATION, AND ELEVATED N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE
• EMPAGLIFLOZIN AND CARDIAC REMODELLING IN PEOPLE WITHOUT DIABETES (EMPA-HEART 2)
• SONOTHROMBOLYSIS IN PATIENTS WITH AN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

View on source registry